Compare VUZI & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VUZI | PEPG |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 163.5M |
| IPO Year | 2009 | 2022 |
| Metric | VUZI | PEPG |
|---|---|---|
| Price | $1.88 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.19 |
| AVG Volume (30 Days) | 952.5K | ★ 1.0M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,280,611.00 | N/A |
| Revenue This Year | $8.49 | N/A |
| Revenue Next Year | $68.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.14 | N/A |
| 52 Week Low | $1.80 | $1.31 |
| 52 Week High | $5.62 | $7.80 |
| Indicator | VUZI | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 45.65 |
| Support Level | N/A | $2.24 |
| Resistance Level | $2.48 | $2.62 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 15.49 | 25.33 |
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices and third-party original design manufacturer (ODM) and original equipment manufacturer (OEM) devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.